Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First steps towards a vaccine for pancreatic cancer

22.09.2003


Research carried out in the United States has raised the hope that one day there could be a vaccine against pancreatic cancer – one of the most difficult cancers to treat successfully.



Dr Robert Maki told ECCO12 – The European Cancer Conference - today (Monday 22 September) that preliminary work with a cancer vaccine created from a heat-shock protein1 taken from the patient’s own tumour had resulted in one patient out of the ten vaccinated still alive and without disease after five years, and two more alive and without disease after more than two years. The typical survival after surgery for pancreas cancer is 14-15 months.

However, Dr Maki warned that patients should not get excited about the results of this research as it was too early to tell whether it would be possible to create a vaccine that could be used on all pancreatic cancer patients, and the patients involved in the trial had been carefully selected and might have been ones that would have done well anyway.


Dr Maki, an assistant member in the division of GI oncology in the department of medicine, and co-director of the sarcoma programme at the Memorial Sloan-Kettering Cancer Center in New York, USA, told delegates that he and his colleagues had run a phase I trial on 10 pancreatic patients using a vaccine based on a heat-shock protein called HSPPC-96 taken from the tumour of each patient (i.e. autologous).

Initial problems in creating the vaccine meant that the study was delayed half way through the study to improve the vaccine-making process. Dr Maki said: “The problem is that the pancreas makes digestive enzymes that destroy proteins . . . in other words, the pancreatic tumour cells themselves can destroy the vaccine you are trying to make, if you do not handle the tumour tissue carefully and quickly. With improvement in the vaccine purification process, most patients with the primary pancreatic cancer enrolled on the study were able to receive vaccinations.”

First, surgeons operated to remove completely the primary tumour, and then the patients were vaccinated within eight weeks of surgery. As far as doctors could tell, the patients were disease-free at the time of their vaccinations. None of the patients suffered side effects that limited the dose of the vaccine, and none had chemotherapy or radiotherapy.

Dr Maki said: “Tests on the patients showed that at least some people we examined made a response against the vaccine and therefore, hopefully, against the cancer. However, we will only get a better picture of the efficacy of this vaccine when we have the clinical results from a larger study.” The overall survival for the 10 patients was two and a half years, in comparison to 14.3 months, the historical average.

“Over 95% of people with pancreatic cancer die, typically within two years of diagnosis, and mortality is still about 90% even for those who have complete removal of their pancreatic cancer. So the finding of even a few patients surviving two years or more is promising regarding the usefulness of this vaccine after removal of the cancer. However, and this is a big however, we may be biased in who we selected for the study. Only people who could have an operation were eligible; we screened out people who had evidence of spread of tumor before they entered the study. Perhaps, just by chance, we got a few people who were destined to do well. So enthusiasm about any phase II study has to be tempered by the fact that you need a proper randomized study to determine the vaccine’s usefulness,” he said.

HSPPC-96 has been shown to have quite a dramatic effect in some patients with metastatic melanoma and so Dr Maki hopes that trials could be run to further test its efficacy against pancreatic cancer as well. In the meantime, until a larger study has been run, it will not be known for certain whether this vaccine has real potential against pancreatic cancer. Trials are also underway to test the vaccine in the treatment of kidney cancer.

The story of this vaccine is a good example of how earlier discoveries at the lab bench can eventually translate into potential new therapies for patients. Dr Maki’s PhD was based on cloning and purifying the human HSPCC-96 molecule. “It is nice to see that well over 10 years after my PhD, this interesting molecule is undergoing examination in the clinic. It is gratifying to see the studies move from the bench to patients, where I hope some benefit will be seen. Similarly, this same technique could be used in preparing vaccines against infectious diseases – another very large area of potential use for these vaccines.”

Mary Rice | alfa
Further information:
http://www.fecs.be/conferences/ecco12/media_updates.shtml

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>